SUmmary Status Subcommittee
The Cancer Immunotherapy Guidelines Non-Small Cell Lung Cancer Task Force is currently developing a consensus statement specific to lung cancer, anticipated for publication in 2018.
This consensus statement will provide expert evidence-based recommendations for the use of immunotherapies including nivolumab, pembrolizumab and atezolizumab. This statement will give recommendations for patient selection, toxicity management, clinical end points and sequencing or combination of therapies.
Robert A. Anders, MD, PhDJohns Hopkins University School of Medicine
Sarah Bonerigo, PAJohns Hopkins University School of Medicine
Steven M. Dubinett, MDDavid Geffen School of Medicine at UCLA
Leena Gandhi, MD, PhDDana-Farber Cancer Institute
Matthew D. Hellmann, MDMemorial Sloan Kettering Cancer Center
Shakuntala Malik, MDNational Cancer Institute, National Institutes of Health
Vassiliki Papadimitrakopoulou, MDThe University of Texas MD Anderson Cancer Center
Lawrence H. Schwartz MDColumbia University College of Physicians and Surgeons
Beow Yong Yeap, ScDMassachusetts General Hospital, Harvard Medical School
Scott J. Antonia, MD, PhDMoffitt Cancer Center
Marianne Davies, NPYale Cancer Center
Edward Garon, MDDavid Geffen School of Medicine at UCLA
Fred R. Hirsch, MD, PhDUniversity of Colorado School of Medicine
Joel Neal, MD, PhDStanford School of Medicine
David L Rimm, MD, PhDYale University School of Medicine
Boris Sepesi, MD, FACSThe University of Texas MD Anderson Cancer Center
Key points from SITC's Cancer Immunotherapy Guidelines have been distilled into Pocket Guides. These condensed, easily accessible versions of the full Cancer Immunotherapy Guidelines are a quick-reference tool available in both digital and print.
Download SITC's Cancer Immunotherapy Pocket Guides on any desktop or mobile device free today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guides
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org